Financial Review: Corbus Pharmaceuticals (NASDAQ:CRBP) vs. Lexeo Therapeutics (NASDAQ:LXEO)

Corbus Pharmaceuticals (NASDAQ:CRBP) and Lexeo Therapeutics (NASDAQ:LXEO) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, analyst recommendations, profitability, risk, valuation, institutional ownership and dividends.

Earnings and Valuation

This table compares Corbus Pharmaceuticals and Lexeo Therapeutics”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Corbus Pharmaceuticals	N/A	N/A	-$78.54 million	($5.82)	-1.95
Lexeo Therapeutics	N/A	N/A	-$99.96 million	($1.45)	-3.52

Lexeo Therapeutics is trading at a lower price-to-earnings ratio than Corbus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

64.6% of Corbus Pharmaceuticals shares are held by institutional investors. Comparatively, 60.7% of Lexeo Therapeutics shares are held by institutional investors. 3.5% of Corbus Pharmaceuticals shares are held by company insiders. Comparatively, 5.3% of Lexeo Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Volatility & Risk

Corbus Pharmaceuticals has a beta of 2.68, indicating that its share price is 168% more volatile than the S&P 500. Comparatively, Lexeo Therapeutics has a beta of 1.52, indicating that its share price is 52% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of current recommendations and price targets for Corbus Pharmaceuticals and Lexeo Therapeutics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Corbus Pharmaceuticals	2	0	9	1	2.75
Lexeo Therapeutics	1	0	7	1	2.89

Corbus Pharmaceuticals currently has a consensus price target of $42.89, indicating a potential upside of 277.88%. Lexeo Therapeutics has a consensus price target of $18.88, indicating a potential upside of 269.37%. Given Corbus Pharmaceuticals’ higher probable upside, research analysts clearly believe Corbus Pharmaceuticals is more favorable than Lexeo Therapeutics.

Profitability

This table compares Corbus Pharmaceuticals and Lexeo Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Corbus Pharmaceuticals	N/A	-70.89%	-61.78%
Lexeo Therapeutics	N/A	-47.48%	-41.72%

Summary

Corbus Pharmaceuticals beats Lexeo Therapeutics on 6 of the 11 factors compared between the two stocks.

About Corbus Pharmaceuticals

Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.

About Lexeo Therapeutics

Lexeo Therapeutics, Inc. operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene. It also develops LX1001, an AAVrh10-based gene therapy candidate for the treatment of APOE4 homozygous; LX1020, a gene therapy candidate for the treatment of APOE4 homozygous; LX1021 for the treatment of APOE4 homozygotes; and LX1004 for the treatment of CLN2 Batten disease. The company was incorporated in 2017 and is based in New York, New York.